{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:14:20Z","timestamp":1790723660896,"version":"4.1.0"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.blre.2019.100618","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T19:51:31Z","timestamp":1571169091000},"page":"100618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Paradigm shift for the treatment of hereditary haemophilia: Towards precision medicine"],"prefix":"10.1016","volume":"39","author":[{"given":"Gaia","family":"Spadarella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Di Minno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella","family":"Milan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicoletta","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariateresa","family":"Polimeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Castaldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Di Minno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.blre.2019.100618_bb0005","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The haemophilias \u2013 from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100618_bb0010","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2019.100618_bb0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1750-1172-7-24","article-title":"Past, present and future of haemophilia: a narrative review","volume":"7","author":"Franchini","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.blre.2019.100618_bb0020","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/j.1538-7836.2011.04214.x","article-title":"A randomized clinical trial of prophylaxis in children with haemophilia A (the ESPRIT study)","volume":"9","author":"Gringeri","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0025","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe haemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100618_bb0030","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/blood-2014-08-535328","article-title":"FVIII inhibitors: pathogenesis and avoidance","volume":"125","author":"Astermark","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100618_bb0035","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/jth.13356","article-title":"Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe haemophilia A","volume":"14","author":"Mannucci","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0040","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1182\/asheducation-2016.1.657","article-title":"Haemophilia and inhibitors: current treatment options and potential new therapeutic approaches","volume":"2016","author":"Meeks","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.blre.2019.100618_bb0045","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1111\/j.1365-2516.2009.02100.x","article-title":"Cost of care of haemophilia with inhibitors","volume":"16","author":"Di Minno","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.100618_bb0050","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1111\/hae.12759","article-title":"Health-related quality of life assessment in haemophilia patients on prophylaxis therapy: a systematic review of results from prospective clinical trials","volume":"21","author":"Oladapo","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.100618_bb0055","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1182\/blood.V93.2.564","article-title":"Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor","volume":"93","author":"Beguin","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100618_bb0060","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.thromres.2011.11.028","article-title":"Tissue factor and atherosclerosis: not only vessel wall-derived TF, but also platelet-associated TF","volume":"129","author":"Camera","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2019.100618_bb0065","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1055\/s-0035-1564041","article-title":"The role of tissue factor in atherothrombosis and coronary artery disease: insights into platelet tissue factor","volume":"41","author":"Camera","year":"2015","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2019.100618_bb0070","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1111\/jth.13871","article-title":"Tissue factor-bearing microparticles and inflammation: a potential mechanism for the development of venous thromboembolism in cancer","volume":"15","author":"Date","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0075","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/jth.14296","article-title":"The future of bypassing agents for haemophilia with inhibitors in the era of novel agents","volume":"16","author":"Shapiro","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0080","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1053\/j.tcam.2012.07.005","article-title":"New models of hemostasis","volume":"27","author":"McMichael","year":"2012","journal-title":"Top Companion Anim Med"},{"key":"10.1016\/j.blre.2019.100618_bb0085","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/JBM.S159297","article-title":"An investigational RNAi therapeutic targeting antithrombin for the treatment of haemophilia A and B","volume":"9","author":"Machin","year":"2018","journal-title":"J Blood Med"},{"key":"10.1016\/j.blre.2019.100618_bb0090","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2018-07-820712","article-title":"New therapies using nonfactor products for patients with haemophilia and inhibitors","volume":"133","author":"Nogami","year":"2019","journal-title":"Blood"},{"issue":"Suppl. 4","key":"10.1016\/j.blre.2019.100618_bb0095","first-page":"154","article-title":"Tissue factor pathway inhibitor (TFPI) \u2013 an update","volume":"26","author":"Sandset","year":"1996","journal-title":"Haemostasis"},{"key":"10.1016\/j.blre.2019.100618_bb0100","doi-asserted-by":"crossref","first-page":"3927","DOI":"10.1073\/pnas.1119858109","article-title":"Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with haemophilia","volume":"109","author":"Maroney","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2019.100618_bb0105","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/00001721-199507000-00004","article-title":"Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A","volume":"6","author":"Erhardtsen","year":"1995","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.blre.2019.100618_bb0110","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1182\/blood-2007-07-098913","article-title":"Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with haemophilia A","volume":"111","author":"Prasad","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100618_bb0115","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1111\/jth.12201","article-title":"Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein","volume":"11","author":"Waters","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0120","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.thromres.2012.08.299","article-title":"Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of haemophilia","volume":"130","author":"Gissel","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2019.100618_bb0125","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1111\/j.1538-7836.2012.04790.x","article-title":"Inhibition of tissue factor pathway inhibitor by the aptamer BAX499 improves clotting of hemophilic blood and plasma","volume":"10","author":"Gorczyca","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0130","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1038\/515S168a","article-title":"Thrombosis: balancing act","volume":"515","author":"Willyard","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.blre.2019.100618_bb0135","first-page":"718","article-title":"Preparation and characterization of monoclonal antibody against recombinant human tissue factor pathway inhibitor","volume":"111","author":"Yang","year":"1998","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.blre.2019.100618_bb0140","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/hae.13260","article-title":"Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay","volume":"23","author":"Waters","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.100618_bb0145","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s40265-018-0922-6","article-title":"Inhibition of tissue factor pathway inhibitor (TFPI) as a treatment for haemophilia: rationale with focus on concizumab","volume":"78","author":"Chowdary","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.blre.2019.100618_bb0150","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1182\/blood-2012-01-401620","article-title":"Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit haemophilia model","volume":"119","author":"Hilden","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100618_bb0155","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/jth.14380","article-title":"Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits","volume":"17","author":"Lauritzen","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0160","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejps.2014.02.009","article-title":"Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in cynomolgus monkeys after iv and sc administration","volume":"56","author":"Agerso","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.blre.2019.100618_bb0165","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/jth.12864","article-title":"Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with haemophilia: a randomized first human dose trial","volume":"13","author":"Chowdary","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0170","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1111\/jth.14272","article-title":"A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with haemophilia A","volume":"16","author":"Eichler","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0175","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1208\/s12248-017-0086-4","article-title":"Mechanistic modeling of the pharmacodynamic and pharmacokinetic relationship of tissue factor pathway inhibitor-neutralizing antibody (BAY 1093884) in cynomolgus monkeys","volume":"19","author":"Gu","year":"2017","journal-title":"AAPS J"},{"key":"10.1016\/j.blre.2019.100618_bb0180","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1160\/TH11-09-0671","article-title":"Molecular analysis and genotype-phenotype correlation in patients with antithrombin deficiency from Southern Italy","volume":"107","author":"Castaldo","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0185","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/j.1365-2516.2008.01830.x","article-title":"Inherited antithrombin deficiency: a review","volume":"14","author":"Patnaik","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.100618_bb0190","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1160\/TH09-10-0732","article-title":"Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice","volume":"103","author":"Bolliger","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0195","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in haemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2019.100618_bb0200","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1182\/blood-2012-11-465674","article-title":"Acute and severe coagulopathy in adult mice following silencing of hepatic antithrombin and protein C production","volume":"121","author":"Safdar","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100618_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038104","article-title":"Modulation of mouse coagulation gene transcription following acute in vivo delivery of synthetic small interfering RNAs targeting HNF4alpha and C\/EBPalpha","volume":"7","author":"Safdar","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2019.100618_bb0210","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1055\/s-0037-1604053","article-title":"Emerging therapeutic strategies in the treatment of haemophilia A","volume":"43","author":"Muczynski","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2019.100618_bb0215","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1056\/NEJMcibr1505657","article-title":"Targeting antithrombin to treat haemophilia","volume":"373","author":"Ragni","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100618_bb0220","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of antithrombin in haemophilia A or B with RNAi therapy","volume":"377","author":"Pasi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100618_bb0225","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1182\/blood.V128.22.2572.2572","article-title":"Fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of haemophilia: updated results from a phase 1 and phase 1\/2 extension study in patients without inhibitors","volume":"128","author":"Ragni","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100618_bb0230","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1182\/blood.V128.22.1397.1397","article-title":"Fitusiran, an investigational RNAi therapeutic targeting antithrombin for the treatment of haemophilia: updated results from a phase 1 and phase 1\/2 extension study in patients with inhibitors","volume":"128","author":"Pasi","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100618_bb0235","series-title":"Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Haemophilia: Interim Results from a Phase 2 Extension Study in Patients with Haemophilia A or B with and Without Inhibitors","author":"Pasi","year":"2017"},{"key":"10.1016\/j.blre.2019.100618_bb0240","doi-asserted-by":"crossref","first-page":"307","DOI":"10.5482\/20170004","article-title":"Thromboembolic risks of non-factor replacement therapies in haemophilia","volume":"37","author":"Tiede","year":"2017","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.blre.2019.100618_bb0245","series-title":"World Federation of Haemophilia","article-title":"Alnylam suspends fitusiran dosing due to thrombotic event in phase 2 open-label extension study","year":"2017"},{"key":"10.1016\/j.blre.2019.100618_bb0250","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1160\/TH17-01-0030","article-title":"Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX\/IXa and X\/Xa, emicizumab, depends on its ability to bridge the antigens","volume":"117","author":"Kitazawa","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0255","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s12913-015-1134-3","article-title":"Costs and utilization of treatment in patients with haemophilia","volume":"15","author":"Rocha","year":"2015","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.blre.2019.100618_bb0260","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a haemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.blre.2019.100618_bb0265","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2014-07-585737","article-title":"Anti-factor IXa\/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired haemophilia A","volume":"124","author":"Muto","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100618_bb0270","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/jth.12474","article-title":"Anti-factor IXa\/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a haemophilia A model and the possibility of routine supplementation","volume":"12","author":"Muto","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0275","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/blood-2015-06-650226","article-title":"A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects","volume":"127","author":"Uchida","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100618_bb0280","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1056\/NEJMoa1511769","article-title":"Factor VIII-mimetic function of humanized bispecific antibody in haemophilia A","volume":"374","author":"Shima","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100618_bb0285","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jpeds.2017.08.053","article-title":"Emicizumab prophylaxis overcomes factor VIII inhibitors in haemophilia A","volume":"190","author":"Shima","year":"2017","journal-title":"J Pediatr"},{"key":"10.1016\/j.blre.2019.100618_bb0290","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1182\/bloodadvances.2017006684","article-title":"Long-term safety and efficacy of emicizumab in a phase 1\/2 study in patients with haemophilia A with or without inhibitors","volume":"1","author":"Shima","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2019.100618_bb0295","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in haemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100618_bb0300","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s40262-017-0616-3","article-title":"A Pharmacometric approach to substitute for a conventional dose-finding study in rare diseases: example of phase III dose selection for emicizumab in haemophilia A","volume":"57","author":"Yoneyama","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.blre.2019.100618_bb0305","first-page":"1071","article-title":"Emicizumab prophylaxis in adolescent\/adult patients with haemophilia A previously receiving episodic or prophylactic bypassing agent treatment: updated analyses from the HAVEN 1 study","volume":"130","author":"Mancuso","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100618_bb0310","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.85.85","article-title":"HAVEN 2 updated analysis: multicenter, open-label, phase 3 study to evaluate efficacy, safety and pharmacokinetics of subcutaneous administration of emicizumab prophylaxis in pediatric patients with haemophilia A with inhibitors","volume":"130","author":"Young","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100618_bb0315","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrd.2018.4","article-title":"2017 FDA drug approvals","volume":"17","author":"Mullard","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.blre.2019.100618_bb0320","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have haemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100618_bb0325","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1177\/2040620718799997","article-title":"The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with haemophilia A","volume":"9","author":"Knight","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.blre.2019.100618_bb0330","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.86.86","article-title":"Emicizumab subcutaneous dosing every 4 weeks for the management of haemophilia A: preliminary data from the pharmacokinetic run-in cohort of a multicenter, open-label, phase 3 study (HAVEN 4)","volume":"130","author":"Jimenez-Yuste","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100618_bb0335","unstructured":"Alnylam Pharmaceuticals I. Alnylam Provides Pipeline Update on Fitusiran and Givosiran Investigational RNAi Therapeutic Programs Business Wire: Cambridge, MA."},{"key":"10.1016\/j.blre.2019.100618_bb0340","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/hae.13641","article-title":"Emicizumab: review of the literature and critical appraisal","volume":"25","author":"Rodriguez-Merchan","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.100618_bb0345","first-page":"MP","article-title":"Thrombin generation response with the addition of bypassing agents in plasma of patients treated with fitusiran","author":"Qian","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.100618_bb0350","first-page":"3668","article-title":"Use of bypassing agents prior to and post bypassing agent dosing guidance during emicizumab prophylaxis: analyses from the HAVEN 1 study","volume":"130","author":"Callaghan","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100618_bb0355","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1538-7836.2009.03703.x","article-title":"Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe haemophilia A: influences of variance in pharmacokinetics and treatment regimens","volume":"8","author":"Collins","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0360","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1538-7836.2008.03270.x","article-title":"Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe haemophilia A","volume":"7","author":"Collins","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0365","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.blre.2018.08.003","article-title":"Attempting to remedy sub-optimal medication adherence in haemophilia: the rationale for repeated ultrasound visualisations of the patient\u2019s joint status","volume":"33","author":"Di Minno","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2019.100618_bb0370","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1055\/s-0029-1222609","article-title":"Interpatient phenotypic inconsistency in severe congenital haemophilia: a systematic review of the role of inherited thrombophilia","volume":"35","author":"Franchini","year":"2009","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2019.100618_bb0375","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1055\/s-2008-1066024","article-title":"The phenotypic heterogeneity of severe haemophilia","volume":"34","author":"Jayandharan","year":"2008","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2019.100618_bb0380","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1055\/s-0034-1395349","article-title":"Phenotypic heterogeneity of hemostasis in severe haemophilia","volume":"41","author":"Nogami","year":"2015","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2019.100618_bb0385","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1055\/s-0037-1615015","article-title":"Small deletion\/insertion mutations within poly-A runs of the factor VIII gene mitigate the severe haemophilia A phenotype","volume":"79","author":"Oldenburg","year":"1998","journal-title":"Thromb Haemost"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2019.100618_bb0390","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1538-7836.2007.02503.x","article-title":"Phenotypic heterogeneity in severe haemophilia","volume":"5","author":"van den Berg","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0395","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1538-7836.2010.03767.x","article-title":"Severe haemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile","volume":"8","author":"Santagostino","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0400","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3324\/haematol.12356","article-title":"Interactions between genotype and phenotype in bleeding and thrombosis","volume":"93","author":"Franchini","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.blre.2019.100618_bb0405","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1365-2516.2010.02250.x","article-title":"F8 mRNA studies in haemophilia A patients with different splice site mutations","volume":"16","author":"Castaman","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.100618_bb0410","first-page":"565","article-title":"Partial correction of a severe molecular defect in haemophilia A, because of errors during expression of the factor VIII gene","volume":"60","author":"Young","year":"1997","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.blre.2019.100618_bb0415","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2011-09-379453","article-title":"F8 gene mutation type and inhibitor development in patients with severe haemophilia A: systematic review and meta-analysis","volume":"119","author":"Gouw","year":"2012","journal-title":"Blood"},{"issue":"Suppl. 77","key":"10.1016\/j.blre.2019.100618_bb0420","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/ejh.12501","article-title":"Strategies for reducing inhibitor formation in severe haemophilia","volume":"94","author":"Tunstall","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2019.100618_bb0425","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1111\/jth.12317","article-title":"Haemophilia A and haemophilia B: focus on arthropathy and variables affecting bleeding severity and prophylaxis","volume":"11","author":"Escobar","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0430","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.thromres.2017.05.038","article-title":"Modifiers of clinical phenotype in severe congenital haemophilia","volume":"156","author":"Franchini","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2019.100618_bb0435","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1182\/blood-2009-04-217075","article-title":"Is VIII worse than IX?","volume":"114","author":"Makris","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100618_bb0440","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/hae.12133","article-title":"Is haemophilia B less severe than haemophilia A?","volume":"19","author":"Mannucci","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.100618_bb0445","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1056\/NEJM198204013061306","article-title":"Leyden: a sex-linked hereditary disorder that improves after puberty","volume":"306","author":"Briet","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100618_bb0450","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.1073\/pnas.89.14.6300","article-title":"Disruption of a binding site for hepatocyte nuclear factor 4 results in haemophilia B Leyden","volume":"89","author":"Reijnen","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.blre.2019.100618_bb0455","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/j.1538-7836.2005.01181.x","article-title":"Does activated protein C-resistant factor V contribute to thrombin generation in hemophilic plasma?","volume":"3","author":"Bos","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0460","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1111\/j.1538-7836.2005.01639.x","article-title":"Factor V Leiden improves in vivo hemostasis in murine haemophilia models","volume":"3","author":"Schlachterman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0465","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1182\/blood.V90.8.3067","article-title":"An in vitro analysis of the combination of haemophilia A and factor V(LEIDEN)","volume":"90","author":"van \u2019t Veer","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100618_bb0470","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1055\/s-0038-1649922","article-title":"Low prevalence of the factor V Leiden mutation among \u201csevere\u201d haemophiliacs with a \u201cmilder\u201d bleeding diathesis","volume":"74","author":"Arbini","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0475","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1055\/s-0037-1613824","article-title":"Effect of the factor V Leiden mutation on the clinical expression of severe haemophilia A","volume":"83","author":"Lee","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0480","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood.V88.4.1183.bloodjournal8841183","article-title":"Moderation of haemophilia A phenotype by the factor V R506Q mutation","volume":"88","author":"Nichols","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100618_bb0485","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood.V99.4.1499","article-title":"Catheter-related thrombosis in children with haemophilia A: evidence of a multifactorial disease","volume":"99","author":"Ettingshausen","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100618_bb0490","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1160\/TH04-03-0148","article-title":"Thrombotic complications in patients with hereditary bleeding disorders","volume":"92","author":"Franchini","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0495","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/(SICI)1096-8652(199711)56:3<189::AID-AJH11>3.0.CO;2-6","article-title":"Cerebral infarct associated with factor V Leiden mutation in a boy with haemophilia A","volume":"56","author":"Olcay","year":"1997","journal-title":"Am J Hematol"},{"key":"10.1016\/j.blre.2019.100618_bb0500","first-page":"201","article-title":"The contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis","volume":"89","author":"Van Rooden","year":"2004","journal-title":"Haematologica"},{"issue":"Suppl. 4","key":"10.1016\/j.blre.2019.100618_bb0505","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2516.2004.00989.x","article-title":"How to evaluate phenotype-genotype relationship in rare coagulation haemorrhagic disorders: examples from FVII deficiency","volume":"10","author":"Bernardi","year":"2004","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.100618_bb0510","doi-asserted-by":"crossref","first-page":"4014","DOI":"10.1182\/blood-2003-04-1199","article-title":"Coinheritance of Factor V (FV) Leiden enhances thrombin formation and is associated with a mild bleeding phenotype in patients homozygous for the FVII 9726+5G>A (FVII Lazio) mutation","volume":"102","author":"Castoldi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.blre.2019.100618_bb0515","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.cca.2009.02.009","article-title":"Modulation of clinical phenotype of Glanzmann\u2019s thrombasthenia by thrombogenic mutations","volume":"403","author":"Kannan","year":"2009","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.blre.2019.100618_bb0520","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/jth.13581","article-title":"Variation in baseline factor VIII concentration in a retrospective cohort of mild\/moderate haemophilia A patients carrying identical F8 mutations","volume":"15","author":"Loomans","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0525","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1055\/s-0033-1354426","article-title":"Defining severity of haemophilia: more than factor levels","volume":"39","author":"Pavlova","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2019.100618_bb0530","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1055\/s-0032-1305782","article-title":"Infection and inflammation as risk factors for thrombosis and atherosclerosis","volume":"38","author":"Levi","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2019.100618_bb0535","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.dld.2015.03.006","article-title":"Viral hepatitis and anti-phospholipid antibodies positivity: a systematic review and meta-analysis","volume":"47","author":"Ambrosino","year":"2015","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.blre.2019.100618_bb0540","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1160\/TH16-03-0185","article-title":"The risk of venous thromboembolism in patients with hepatitis C. A systematic review and meta-analysis","volume":"116","author":"Ambrosino","year":"2016","journal-title":"Haemostasis"},{"key":"10.1016\/j.blre.2019.100618_bb0545","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1055\/s-0035-1556729","article-title":"Chronic infection and venous thromboembolic disease","volume":"41","author":"Epaulard","year":"2015","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.blre.2019.100618_bb0550","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2796.1994.tb00815.x","article-title":"A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group","volume":"236","author":"Aledort","year":"1994","journal-title":"J Intern Med"},{"key":"10.1016\/j.blre.2019.100618_bb0555","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jth.14135","article-title":"Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies","volume":"16","author":"Nogami","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0560","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1111\/jth.14022","article-title":"Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa\/factor X bispecific antibody emicizumab","volume":"16","author":"Nogami","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0565","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1373\/clinchem.2017.284356","article-title":"Advances in the treatment of haemophilia: implications for laboratory testing","volume":"65","author":"Tripodi","year":"2019","journal-title":"Clin Chem"},{"key":"10.1016\/j.blre.2019.100618_bb0570","first-page":"163","article-title":"Mode of enhancement in the global hemostatic potentials with concomitant use of bypassing agents and emicizumab in haemophilia A patients with inhibitor evaluated by ROTEM","author":"Yada","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.blre.2019.100618_bb0575","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2516.2011.02682.x","article-title":"Identification and long-term observation of early joint damage by magnetic resonance imaging in clinically asymptomatic joints in patients with haemophilia A or B despite prophylaxis","volume":"18","author":"Olivieri","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.100618_bb0580","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0169880","article-title":"Adherence to prophylaxis in adolescents and young adults with severe haemophilia: a quantitative study with patients","volume":"12","author":"van Os","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.blre.2019.100618_bb0585","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1056\/NEJMp1500523","article-title":"A new initiative on precision medicine","volume":"372","author":"Collins","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2019.100618_bb0590","doi-asserted-by":"crossref","first-page":"411","DOI":"10.3324\/haematol.2016.156000","article-title":"Tailoring of medical treatment: hemostasis and thrombosis towards precision medicine","volume":"102","author":"Di Minno","year":"2017","journal-title":"Haematologica"},{"issue":"Suppl. 5","key":"10.1016\/j.blre.2019.100618_bb0595","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1365-2516.2012.02887.x","article-title":"Difficult clinical challenges in haemophilia: international experiential perspectives","volume":"18","author":"Forsyth","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.100618_bb0600","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000073575","article-title":"The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability","volume":"32","author":"Hemker","year":"2002","journal-title":"Pathophysiol Haemost Thromb"},{"key":"10.1016\/j.blre.2019.100618_bb0605","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.thromres.2008.07.013","article-title":"Intraindividual thrombin generation measurement variability in healthy adults over a one year period","volume":"124","author":"Dargaud","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.blre.2019.100618_bb0610","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2516.2009.02191.x","article-title":"Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A","volume":"16","author":"Bjorkman","year":"2010","journal-title":"Haemophilia"},{"key":"10.1016\/j.blre.2019.100618_bb0615","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/ejh.12359","article-title":"Innovative approach for improved rFVIII concentrate","volume":"93","author":"Morfini","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2019.100618_bb0620","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/clpt.1994.134","article-title":"Pharmacologic target-mediated drug disposition","volume":"56","author":"Levy","year":"1994","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.blre.2019.100618_bb0625","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2141.2007.06693.x","article-title":"Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients","volume":"138","author":"Shetty","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.blre.2019.100618_bb0630","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1001\/jama.2015.3382","article-title":"A public health perspective on a national precision medicine cohort: balancing long-term knowledge generation with early health benefit","volume":"313","author":"Khoury","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.blre.2019.100618_bb0635","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1016\/S0140-6736(15)60722-X","article-title":"Aligning incentives to fulfil the promise of personalised medicine","volume":"385","author":"Dzau","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.blre.2019.100618_bb0640","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1182\/bloodadvances.2018015859","article-title":"Emicizumab should be prescribed independent of immune tolerance induction","volume":"2","author":"Le Quellec","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2019.100618_bb0645","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/hae.12970","article-title":"The evolution of comprehensive haemophilia care in the United States: perspectives from the frontline","volume":"22","author":"Aledort","year":"2016","journal-title":"Haemophilia"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X19301328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X19301328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:24:23Z","timestamp":1759436663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X19301328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":129,"alternative-id":["S0268960X19301328"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2019.100618","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Paradigm shift for the treatment of hereditary haemophilia: Towards precision medicine","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2019.100618","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100618"}}